Literature DB >> 23211716

Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis.

A Toczek1, H Cox, P du Cros, G Cooke, N Ford.   

Abstract

BACKGROUND: Scaling up treatment for multidrug-resistant tuberculosis is a global health priority. However, current treatment regimens are long and associated with side effects, and default rates are consequently high. This systematic review aimed to identify strategies for reducing treatment default.
METHODS: We conducted a systematic search up to May 2012 to identify studies describing interventions to support patients receiving treatment for multidrug-resistant tuberculosis (MDR-TB). The potential influence of study interventions were explored through subgroup analyses.
RESULTS: A total of 75 studies provided outcomes for 18,294 patients across 31 countries. Default rates ranged from 0.5% to 56%, with a pooled proportion of 14.8% (95%CI 12.4-17.4). Strategies identified to be associated with lower default rates included the engagement of community health workers as directly observed treatment (DOT) providers, the provision of DOT throughout treatment, smaller cohort sizes and the provision of patient education.
CONCLUSION: Current interventions to support adherence and retention are poorly described and based on weak evidence. This review was able to identify a number of promising, inexpensive interventions feasible for implementation and scale-up in MDR-TB programmes. The high default rates reported from many programmes underscore the pressing need to further refine and evaluate simple intervention packages to support patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23211716     DOI: 10.5588/ijtld.12.0537

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  66 in total

1.  The scourge of tuberculosis and anti-tuberculosis drug resistance in Eastern Europe.

Authors:  Helen Cox; Nathan Ford
Journal:  Public Health Action       Date:  2014-10-21

2.  Improving outcomes for multi-drug-resistant tuberculosis in the Peruvian Amazon - a qualitative study exploring the experiences and perceptions of patients and healthcare professionals.

Authors:  Thomas W McNally; Gilles de Wildt; Graciela Meza; Connie M D Wiskin
Journal:  BMC Health Serv Res       Date:  2019-08-22       Impact factor: 2.655

3.  Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa.

Authors:  M Loveday; K Wallengren; J Brust; J Roberts; A Voce; B Margot; J Ngozo; I Master; G Cassell; N Padayatchi
Journal:  Int J Tuberc Lung Dis       Date:  2015-02       Impact factor: 2.373

4.  Multidrug-resistant tuberculosis: Treatment and outcomes of 93 patients.

Authors:  Sarah K Brode; Robert Varadi; Jane McNamee; Nina Malek; Sharon Stewart; Frances B Jamieson; Monica Avendano
Journal:  Can Respir J       Date:  2014-12-10       Impact factor: 2.409

5.  Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia.

Authors:  G Kuchukhidze; A M V Kumar; P de Colombani; M Khogali; U Nanava; H M Blumberg; R R Kempker
Journal:  Public Health Action       Date:  2014-10-21

6.  Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus.

Authors:  A Khaliaukin; A M V Kumar; A Skrahina; H Hurevich; V Rusovich; J Gadoev; D Falzon; M Khogali; P de Colombani
Journal:  Public Health Action       Date:  2014-10-21

7.  Predictors of mortality and loss to follow-up among drug resistant tuberculosis patients in Oromia Hospitals, Ethiopia: A retrospective follow-up study.

Authors:  Demelash Woldeyohannes; Yohannes Tekalegn; Biniyam Sahiledengle; Tesfaye Assefa; Rameto Aman; Zeleke Hailemariam; Lillian Mwanri; Alemu Girma
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

8.  Multidrug-resistant tuberculosis patients' views of interventions to reduce treatment loss to follow-up.

Authors:  T Tupasi; A M C G Garfin; J M Mangan; R Orillaza-Chi; L C Naval; G I Balane; R Basilio; A Golubkov; E S Joson; W-J Lew; V Lofranco; M Mantala; S Pancho; J N Sarol; A Blumberg; D Burt; E V Kurbatova
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

9.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

10.  Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality.

Authors:  Carole D Mitnick; Molly F Franke; Michael L Rich; Felix A Alcantara Viru; Sasha C Appleton; Sidney S Atwood; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Hamish S F Fraser; Jennifer J Furin; Dalia Guerra; Rocio M Hurtado; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Kwonjune J Seung; Sonya S Shin; Alexander Sloutsky; Arielle W Tolman; Mercedes C Becerra
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.